{"analyses":[{"ciLowerLimit":"-3.3","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"9.2","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1752","paramType":"Difference in percentages","paramValue":"2.9","statisticalMethod":"Miettinen & Nurminen method"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.1","upperLimit":"17.6","value":"12.3"},{"groupId":"OG001","lowerLimit":"5.8","upperLimit":"14.3","value":"9.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"description":"Overall Response Rate (ORR), based on BICR assessment per RECIST 1.1, was defined as the percentage of participants who had a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to \\~2 years).","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines.","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"All participants with PD-L1 CPS ≥1 who were included in a treatment group at randomization","reportingStatus":"POSTED","timeFrame":"Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019)","title":"Overall Response Rate Per RECIST 1.1 in Participants With PD-L1 CPS ≥1","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}